X4 Pharmaceuticals, Inc (XFOR) earnings date
Mar 23, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 21 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 36 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | before open | 31 | 8-K |
| Q4 FY2024 | Tue, Mar 25, 2025 | before open | 84 | 8-K |
| Q3 FY2024 | Wed, Nov 13, 2024 | before open | 44 | 8-K |
| Q2 FY2024 | Thu, Aug 8, 2024 | before open | 39 | 8-K |
| Q1 FY2024 | Tue, May 7, 2024 | before open | 37 | 8-K |
| Q4 FY2023 | Thu, Mar 21, 2024 | before open | 81 | 8-K |
| Q3 FY2023 | Thu, Nov 9, 2023 | before open | 40 | 8-K |
What they guided beta
| Q3 FY2025 | "An increase in the enrollment target for the pivotal Phase 3 4WARD study to 176 patients with enrollment now expected to be completed in third quarter of 2026." exhibit |
| Q3 FY2025 | "With a strengthened cash runway to the end of 2028, X4 is now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028." exhibit |
| Q1 FY2025 | "Document Exhibit 99.1 X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates 4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, Mass., May 1, 2025 – X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases " exhibit |
| Q1 FY2025 | "X4 continues to expect full enrollment in the trial in the third or fourth quarter of 2025, and disclosure of top-line data in the second half of 2026." exhibit |
| Q1 FY2025 | "The patent is expected to expire in the U.S. in March of 2041; similar patent applications are pending in Europe , China, Japan, and Canada ." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/XFOR
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/XFOR
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/XFOR/"><img src="https://veritasdata.dev/embed/XFOR.svg" alt="XFOR earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/XFOR/)
Script
<script async src="https://veritasdata.dev/embed/XFOR.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/XFOR"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.